КЕНИГ Герхард (US),ЧЕСУОРТ Ричард (US),ШАПИРО Гидеон (US)
申请号：
RU2014122858/15
公开号：
RU2014122858A
申请日:
2014.06.04
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating negative symptoms associated with schizophrenia in a patient in need thereof, comprising: administering to a specified patient a daily dose in the range from 0.1 mg to 3.0 mg of (R) -7-chloro-N- (quinuclidin-3- il) benzo [c] thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the pharmaceutically acceptable salt of (R) -7-chloro-N- (quinuclidin-3-yl) benzo [c] thiophene-2-carboxamide is: (R) -7-chloro-N- ( quinuclidin-3-yl) benzo [v] thiophene-2-carboxamide hydrochloride, (R) -7-chloro-N- (quinuclidin-3-yl) benzo [v] thiophen-2-carboxamide hydrochloride monohydrate or (R) - 7-chloro-N- (quinuclidin-3-yl) benzo [c] thiophen-2-carboxamide hydrochloride solvate. 3. A method according to claim 2, wherein a pharmaceutically acceptable salt of (R) -7-chloro-N- (quinuclidin-3-yl) benzo [v] thiophen-2-carboxamide is administered to a patient. The method of claim 3, wherein the pharmaceutically acceptable salt of (R) -7-chloro-N- (quinuclidin-3-yl) benzo [c] thiophene-2-carboxamide is (R) -7-chloro-N- (quinuclidine -3-yl) benzo [c] thiophene-2-carboxamide hydrochloride. 5. The method of claim 3, wherein the pharmaceutically acceptable salt of (R) -7-chloro-N- (quinuclidin-3-yl) benzo [c] thiophene-2-carboxamide is (R) -7-chloro-N- (quinuclidine -3-yl) benzo [c] thiophene-2-carboxamide hydrochloride monohydrate. 6. The method of claim 5, wherein the daily dose is in the range of 0.3 mg to 1.5 mg. A method according to claim 5, in which the daily dose is presented in the range from 0.7 mg to 1.25 mg. The method of claim 5, wherein the daily dose is in the range of 0.1 mg to 3.0 mg. The method of claim 5, wherein the daily dose is in the range of 1.5 mg to 2.5 mg. The method of claim 5, wherein the daily dose is in the range of 1.75 mg to 2.25 mg. The method of claim 5, wherein the daily dose is in the range of 2.0 mg to 3.0 mg. The method of claim 11. Способ лечения негативных симптомов, связанных с ш
